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Purpose: The purpose of this study is to determine the efficacy of combining topical nepafenac 
with monthly intravitreal injections of ranibizumab or bevacizumab in the treatment of   recalcitrant 
exudative macular degeneration.
Methods: This was a retrospective, consecutive case series of patients with exudative 
  macular degeneration requiring maintenance therapy of antivascular endothelial growth factor 
  (anti-VEGF) injections at least every 6 weeks, who were started on topical nepafenac. Despite 
frequent anti-VEGF dosing, all patients included in the study had persistence of any combina-
tion of the following: intraretinal cysts, subretinal fluid, and/or pigment epithelial detachment. 
Patients underwent pinhole visual acuity, clinical exam, and optical coherence tomography (OCT) 
at baseline and every follow-up visit. Response to therapy was graded by reviewing quantitative 
and qualitative OCT data, and statistical analysis was done with paired Student’s t-test.
Results: Twenty-five patients (average age 77; 14 male and 11 female) were reviewed; the mean 
number of previous injections was 17.4 (range 3–31). Baseline mean visual acuity was 20/55, 
and final mean visual acuity after 3 months of treatment was 20/51 (P = 0.13). Monthly mean 
central foveal thickness measurements were 248, 250, 257, and 247 µm (P = 0.53) at baseline, 
1, 2, and 3 months, respectively. By the end of the 3-month time point, qualitative OCT findings 
on 13 patients treated with nepafenac were classified as stable, 10 as better, and 2 as worse.
Conclusions: There was no significant change in visual acuity or quantitative OCT 
measurements, but there appeared to be a mild trend toward improved anatomy and qualitative 
OCT findings when topical nepafenac was added to monthly anti-VEGF injections in patients 
with persistent intraretinal cysts, subretinal fluid, and/or pigment epithelial detachment. Further 
prospective studies with longer follow-up may be warranted.
Keywords: anti-VEGF, combination therapy, exudative macular degeneration, nonsteroidal 
anti-inflammatory, optical coherence tomography
Introduction
Age-related macular degeneration (AMD) is the leading cause of vision loss in the 
United States, and its prevalence is expected to increase by more than 50% by 2020.1 
The exudative form of AMD, defined by the growth of a choroidal neovascular 
membrane (CNVM) and a subsequent increase in vascular permeability, is present in 
20% of patients and accounts for 90% of severe vision loss in patients with AMD.2 
Vascular endothelial growth factor (VEGF) plays a prominent role in exudative AMD 





for exudative AMD.3–5 Despite monthly treatment, many 
patients continue to have persistent exudation.
Among the multiple factors implicated in neovascular 
AMD, inflammation is known to play an important role in 
CNVM formation.6 A preliminary study of combination 
treatment with anti-VEGF therapy and a nonsteroidal anti-
inflammatory drug (NSAID), topical bromfenac (0.09%) 
(Xibrom®; ISTA Pharmaceuticals Inc., Irvine, CA), reported 
a synergistic effect with both improved visual outcomes 
as well as a decreased need for intravitreal injections.7 
Nepafenac 0.1% (Nevanac®; Alcon Labs, Fort Worth, TX) 
is another topical NSAID used in the treatment of pain 
and inflammation associated with cataract surgery, as it 
has excellent corneal and scleral penetration.8 Nepafenac 
inhibits both COX-1 and COX-2, reducing levels of pros-
taglandins and thromboxanes implicated in angiogenesis. 
We evaluated patients with recalcitrant exudative AMD 
treated with anti-VEGF therapy and topical nepafenac to 
determine the efficacy of combination therapy.
Methods
After obtaining approval of the study protocol by the 
Institutional Review Board of The Methodist Hospital in 
Houston, TX, USA, a retrospective, consecutive review 
of all patients seen at our practice between July 1, 2009, 
and December 31, 2009, was performed. We identified 
patients with exudative AMD who were prescribed off-
label nepafenac three times daily in addition to anti-VEGF 
treatment with ranibizumab (Lucentis; Genentech, Inc., 
South San Francisco, CA) or bevacizumab (Avastin; 
Genentech, Inc.,). All patients included in the study had 
received at least three injections of intravitreal ranibi-
zumab (0.5 mg/0.05 mL) or   intravitreal bevacizumab 
(1.25 mg/0.05 mL) prior to this review and continued to 
require anti-VEGF therapy at least every 6 weeks for per-
sistent exudation. For this study, persistent exudation was 
defined as any combination of the following: intraretinal 
cysts, subretinal fluid (SRF), and/or pigment epithelial 
detachment.9
Patients underwent pinhole visual acuity, clinical 
exam, and optical coherence tomography (OCT) at 
baseline and every follow-up visit, and main outcome 
measures studied were visual outcomes and response to 
therapy as graded by reviewing quantitative and qualita-
tive time-domain OCT data (Stratus; Carl Zeiss Meditec, 
Inc., Dublin, CA). For the purposes of this study, retinal 
thickness in the central subfield was used for quantitative 
OCT measurements, while qualitative OCT grading 
was based on any change in either the number or size of 
intraretinal cysts, amount of SRF, and/or size of pigment 
epithelial detachment.
Pinhole Snellen visual acuities were converted to 
  logarithm of the minimal angle of resolution for   statistical 
analysis, and paired Student’s t-test was used, with 
  significance indicated by P , 0.05.
Results
Twenty-five patients (mean age 77; 14 male and 11 female) 
who completed 3 months of follow-up were identified; there 
were 10 right eyes and 15 left eyes involved in the review 
group (Table 1). The mean number of previous injections 
was 17.4 (range 3–31). Previous intravitreal agents included 
bevacizumab alone, 1 patient; ranibizumab alone, 21 patients; 
and both bevacizumab and ranibizumab, 3 patients. Mean 
visual acuity was 20/55 at baseline, and mean final visual 
acuity after 3 months of topical nepafenac three times daily in 
combination with monthly intravitreal anti-VEGF   treatment 
was 20/51 (P = 0.13). Mean monthly central foveal thickness 
measurements from time-domain OCT were 248, 250, 257, 
and 247 µm at baseline, 1, 2, and 3 months, respectively, with 
no statistical difference between initial and final thickness 
measurements (P = 0.53). Compared to baseline,   qualitative 
OCT findings on 13 patients treated with nepafenac were 
classified as stable, 10 as better, and 2 as worse at the 3-month 
time point.
Discussion
Although anti-VEGF agents have produced better results 
than ever seen before in the treatment of exudative AMD, 
most patients require repeated intravitreal injections at 
regular intervals to maintain the initial visual acuity gains, 
and a subset of patients have persistent fluid despite monthly 
  maintenance treatment.10,11 In addition to the significant 
  burden both to the patient and society of frequent   intravitreal 
anti-VEGF treatment, intravitreal injections also entail 
the rare but potential complications of pain, retinal tear or 
  detachment, and endophthalmitis.12
As multiple pathways, including both angiogenesis and 
inflammation, have been implicated in the progression of 
exudative AMD, different combination therapies focusing 
on anti-VEGF agents plus verteporfin (Visudyne®; Novartis 
Ophthalmics, Bulach, Switzerland) photodynamic therapy 
with or without intravitreal steroids have been studied.13 As 




Use of nepafenac with intravitreal anti-VegF agents
and choroidal hypoperfusion and intravitreal steroids can 
lead to cataract formation and elevated intraocular   pressures, 
a topical anti-inflammatory medication may produce less 
side effects.
A nonrandomized, retrospective 6-month study by 
Grant suggested a synergistic effect for anti-VEGF treat-
ment supplemented with topical bromfenac; patients in the 
combination arm had a statistically significant improvement 
in visual outcomes and a statistically significant decrease in 
the number of injections administered.7 However, another 
study by Zweifel et al concluded that there was no objective 
or subjective benefit to topical bromfenac, and most patients 
discontinued the medicine after 2 months due to lack of 
perceived benefit.14
Nepafenac is a nonsteroidal anti-inflammatory prodrug 
approved for the treatment of postcataract surgery pain and 
inflammation. It has superior corneal penetration compared 
to other NSAIDs and is bioactivated by ocular tissues to 
amfenac.8,15 Studies in rat models have indicated that it 
may play a role in inhibiting ocular neovascularization by 
inhibiting VEGF and retinal angiogenesis,16,17 and a recent 
case report showed topical nepafenac produced regression 
of intraretinal and subretinal macular edema and a reduction 
of fluorescein leakage in exudative AMD.18
In this study, patients continued to receive anti-VEGF 
therapy that was supplemented with topical nepafenac three 
times daily; there were no safety issues or adverse events, 
and all 25 patients included in the review took nepafenac 
for 3 months. There was no significant change in mean 
visual acuity (P = 0.13) or quantitative OCT measurements 
(P = 0.53) of central foveal thickness from the initial visit 
to the final visit. Qualitative grading of OCT results did sug-
gest there was some mild benefit. In most patients, dramatic 
differences in retinal anatomy were not seen on OCT scans; 
23/25 demonstrated stable or improved anatomy, defined as 
fewer or smaller cysts or decreased amount or size of SRF/
pigment epithelial detachment. The other two patients who 
were classified as worsening on qualitative OCT grading 
experienced an increase in intraretinal cysts, but patient 
9 maintained vision, while patient 21 had a mild improve-
ment in final visual acuity. In addition, during the course 
of the study period, patients 17 and 20 had complete but 
Table 1 Demographics, characteristics, and findings of patients
Pt Age Sex Eye Prior Rx VA (initial) VA (final) OCTi, μm OCTf, μm OCT findings Change
1 70 M OD iVL X 11, iVA X 4 20/30−2 20/50−2 158 152 srF same
2 68 M Os iVL X 3 20/25 20/30−2 218 196 srF Better
3 74 F Os iVA X 8 20/70−1 20/80−1 251 232 ir cysts, PeD same
4 89 M Os iVL X 31 20/30−2 20/30−1 222 227 srF, PeD same
5 70 F OD iVL X 26 20/30+2 20/25−2 221 227 srF, PeD Better
6 78 M Os iVL X 19, iVA X 8 20/50−1 20/40 241 235 srF, ir cysts, PeD same
7 75 F Os iVL X 12 20/25−2 20/25−2 229 274 srF, PeD same
8 71 F Os iVL X 28 20/70−2 20/70 225 206 srF, PeD Better
9 84 M OD iVL X 22 20/200 20/200−1 282 311 ir cysts Worse
10 73 M OD iVL X 17 20/30 20/40−1 246 200 srF Better
11 76 F OD iVL X 20 20/30+2 20/25−2 178 165 srF Better
12 76 F OD iVL X 7 20/40+2 20/40−2 255 267 srF, PeD same
13 81 M OD iVL X 3 20/60−2 20/40−2 392 384 srF, ir cysts, PeD Better
14 81 F Os iVL X 22 20/40+1 20/40−2 198 190 srF, ir cysts, PeD same
15 72 M OD iVL X 12 20/60−2 20/60−1 245 233 ir cysts Better
16 81 M Os iVL X 3 20/40−2 20/30−2 260 262 srF, ir cysts same
17 67 F Os iVL X 9 20/30−1 20/25−1 225 151 srF, ir cysts Better
18 73 F Os iVL X 30 20/80 20/60 352 271 srF Better
19 66 M Os iVL X 25 20/50 20/40−1 254 308 srF, ir cysts same
20 80 M Os iVL X 4, iVA X 9 20/200 20/200 173 193 srF, PeD Better
21 88 F Os iVL X 20 20/200 20/100+1 276 331 srF, ir cysts Worse
22 79 M Os iVL X 13 20/200 20/200 198 190 srF, ir cysts same
23 74 M OD iVL X 17 20/200 20/200 5481 5741 ir cysts, PeD same
24 94 F OD iVL X 23 20/40−1 20/30−1 179 140 ir cysts same
25 76 M Os iVL X 28 20/30−1 20/30−2 186 211 srF same
Note: 1OCT measurements taken from heidelberg spectralis (spectralis; heidelberg engineering, heidelberg, germany).
Abbreviations: IVL, intravitreal ranibizumab; IVA, intravitreal bevacizumab; SRF, subretinal fluid; IR, intraretinal; OCT, optical coherence tomography; PED, pigment 
epithelial detachment; VA, visual acuity.Clinical Ophthalmology
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only temporary resolution of SRF; neither of these patients 
experienced any change in visual acuity despite the interval 
changes seen on OCT.
As a retrospective study, there are many inherent 
limitations. There is a potential for selection bias as 
patients were not randomly selected for treatment; all had 
demonstrated lack of response to monthly injections, but 
there were differences in both the number of and the exact 
anti-VEGF agents previously administered. The lack of a 
control group and the small number of patients involved 
prevent us from accurately drawing conclusions about the 
efficacy of the treatment; although 25 patients finished 
3 months of treatment, there were others that were started on 
the drops but discontinued due to lack of perceived effect and/
or cost. There was a mild trend toward improved anatomic 
results based on qualitative OCT findings, although, even 
within the described limitations, we noted no visual benefit 
or significant improvement in quantitative OCT findings 
when adding topical nepafenac to patients receiving monthly 
anti-VEGF injections for exudative AMD. Future prospective 
studies with a control group and longer follow-up time may 
be warranted for further investigation.
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